Uso de boceprevir y telaprevir en pacientes con VHC (aspectos prácticos)

摘要: The European Medicines Agency has recently approved the use of telaprevir (Incivo®, Janssen) and boceprevir (Victrelis®, MSD) combined with pegylated interferon ribavirin in triple therapy as treatment choice patients genotype 1 chronic hepatitis C infection. high efficacy therapy, even cirrhosis or those previously unresponsive to ribavirin, represents a major step forward management However, routine clinical practice, poses challenge requiring detailed knowledge various aspects that differ substantially from standard infection ribavirin. These include profile most common adverse effects, important drug interactions, importance respecting guidelines for withdrawal.